COVID-19 与肝脏：大流行六个月后我们了解多少？
COVID-19 and the liver: What do we know after six months of the pandemic?
机构信息
Department of Immunology, Biomedical Research Institute, National Autonomous University of Mexico, Mexico.
出版信息
Ann Hepatol. 2020 Nov-Dec;19(6):590-591. doi: 10.1016/j.aohep.2020.09.001. Epub 2020 Sep 18.
Abstract
Despite liver injury in patients infected with severe acute respiratory syndrome (SARS) coronavirus (CoV)-2 (SARS-CoV-2) is associated with prolonged hospitalization, and liver dysfunction is mainly described in patients with severe viral disease. How liver abnormalities may affect virus infection is still unknown. Improved understanding of host genetics, lifestyle, underlying comorbidities and adequate follow-up of patients with liver damage are critical in the new scenario of the pandemic virus.
摘要
尽管感染严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）的患者存在肝损伤与住院时间延长有关，且肝功能障碍主要见于重症病毒性疾病患者，但肝异常如何影响病毒感染仍不清楚。在大流行病毒的新形势下，改善对宿主遗传、生活方式、潜在合并症以及肝损伤患者的充分随访的认识至关重要。
相似文献
1
COVID-19 and the liver: What do we know after six months of the pandemic?COVID-19 与肝脏：大流行六个月后我们了解多少？
Ann Hepatol. 2020 Nov-Dec;19(6):590-591. doi: 10.1016/j.aohep.2020.09.001. Epub 2020 Sep 18.
2
[The protocol for prevention, diagnosis and treatment of liver injury in coronavirus disease 2019].[新型冠状病毒肺炎肝损伤防治专家共识]
Zhonghua Gan Zang Bing Za Zhi. 2020 Mar 20;28(3):217-221. doi: 10.3760/cma.j.cn501113-20200309-00095.
3
Clinical insight into the involvement of gut and liver by COVID-19.对2019冠状病毒病累及肠道和肝脏的临床见解。
J Pak Med Assoc. 2020 Jun;70(6):952-953.
4
The liver in times of COVID-19: What hepatologists should know.COVID-19 时期的肝脏：肝病学家应该了解的知识。
Ann Hepatol. 2020 Jul-Aug;19(4):353-358. doi: 10.1016/j.aohep.2020.05.001. Epub 2020 May 18.
5
COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract.COVID-19 大流行：胃肠道的病理生理学和表现。
World J Gastroenterol. 2020 Aug 21;26(31):4579-4588. doi: 10.3748/wjg.v26.i31.4579.
6
Management of venous thromboembolism during the COVID-19 pandemic.2019冠状病毒病大流行期间静脉血栓栓塞的管理
J Vasc Surg Venous Lymphat Disord. 2020 Sep;8(5):897-898. doi: 10.1016/j.jvsv.2020.05.005. Epub 2020 May 23.
7
Gastrointestinal and Hepatic Manifestations of 2019 Novel Coronavirus Disease in a Large Cohort of Infected Patients From New York: Clinical Implications.纽约大量新冠病毒感染患者的2019冠状病毒病的胃肠道和肝脏表现：临床意义
Gastroenterology. 2020 Sep;159(3):1137-1140.e2. doi: 10.1053/j.gastro.2020.05.010. Epub 2020 May 8.
8
Rates of Symptomatic SARS-CoV-2 Infection in Patients With Autoimmune Liver Diseases in Northern Italy: A Telemedicine Study.意大利北部自身免疫性肝病患者中 SARS-CoV-2 感染的症状发生率：一项远程医疗研究。
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2369-2371.e1. doi: 10.1016/j.cgh.2020.05.047. Epub 2020 May 30.
9
Management of Patients with Liver Transplant and Chronic Liver Diseases During COVID-19 Pandemic: A Brief Review.COVID-19 大流行期间肝移植和慢性肝病患者的管理：简要综述。
Arch Iran Med. 2020 Oct 1;23(10):713-717. doi: 10.34172/aim.2020.92.
10
Severe Pneumonia Due to SARS-CoV-2 and Respiratory Syncytial Virus Infection: A Case Report.新型冠状病毒肺炎合并呼吸道合胞病毒感染所致重症肺炎：一例报告
Clin Pediatr (Phila). 2020 Jul;59(8):823-826. doi: 10.1177/0009922820920016. Epub 2020 Apr 15.
引用本文的文献
1
COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?2023 年关于 COVID-19、可能的肝脏途径和酒精滥用，我们了解多少？
Int J Mol Sci. 2024 Feb 12;25(4):2212. doi: 10.3390/ijms25042212.
2
Long COVID: a review and proposed visualization of the complexity of long COVID.长新冠：长新冠复杂性的综述和拟议可视化。
Front Immunol. 2023 Apr 20;14:1117464. doi: 10.3389/fimmu.2023.1117464. eCollection 2023.
3
COVID-19-induced transaminitis and hyperbilirubinemia: Presentation and outcomes.COVID-19 引起的转氨血症和高胆红素血症：表现和结局。
World J Gastroenterol. 2023 Feb 21;29(7):1123-1130. doi: 10.3748/wjg.v29.i7.1123.
4
Outcomes of COVID-19 among patients with liver disease.COVID-19 患者的肝病结局。
World J Gastroenterol. 2023 Feb 7;29(5):815-824. doi: 10.3748/wjg.v29.i5.815.
5
It Can't Be a Coincidence: A Comparison of Cases of Autoimmune Hepatitis After Vaccination Against COVID-19.这不可能是巧合：接种新冠疫苗后自身免疫性肝炎病例的比较
ACG Case Rep J. 2023 Feb 1;10(1):e00965. doi: 10.14309/crj.0000000000000965. eCollection 2023 Jan.
6
Serum biomarkers for nutritional status as predictors in COVID-19 patients before and after vaccination.作为预测指标的营养状况血清生物标志物在COVID-19患者疫苗接种前后的情况。
J Funct Foods. 2023 Feb;101:105412. doi: 10.1016/j.jff.2023.105412. Epub 2023 Jan 10.
7
Ferritin, blood urea nitrogen, and high chest CT score determines ICU admission in COVID-19 positive UAE patients: A single center retrospective study.铁蛋白、血尿素氮和高胸部 CT 评分决定 COVID-19 阳性阿联酋患者入住 ICU：一项单中心回顾性研究。
PLoS One. 2022 Jul 19;17(7):e0269185. doi: 10.1371/journal.pone.0269185. eCollection 2022.
8
Spontaneous rupture of spleen in a patient with COVID-19 disease: case report and review of the literature.1例新型冠状病毒肺炎患者脾脏自发性破裂：病例报告及文献复习
J Surg Case Rep. 2022 Apr 23;2022(4):rjac124. doi: 10.1093/jscr/rjac124. eCollection 2022 Apr.
9
Profiling metabolites and lipoproteins in COMETA, an Italian cohort of COVID-19 patients.分析 COMETA 意大利队列 COVID-19 患者的代谢物和脂蛋白。
PLoS Pathog. 2022 Apr 21;18(4):e1010443. doi: 10.1371/journal.ppat.1010443. eCollection 2022 Apr.
10
COVID-19: Gastrointestinal manifestations, liver injury and recommendations.2019冠状病毒病：胃肠道表现、肝损伤及建议
World J Clin Cases. 2022 Feb 6;10(4):1140-1163. doi: 10.12998/wjcc.v10.i4.1140.
本文引用的文献
1
A systematic review and meta-analysis of the COVID-19 associated liver injury.新型冠状病毒相关肝损伤的系统评价和荟萃分析。
Ann Hepatol. 2020 Nov-Dec;19(6):627-634. doi: 10.1016/j.aohep.2020.08.064. Epub 2020 Aug 31.
2
Impact of obesity on hospitalizations and mortality, due to COVID-19: A systematic review.肥胖对因 COVID-19 导致的住院和死亡的影响：一项系统评价。
Obes Res Clin Pract. 2020 Sep-Oct;14(5):398-403. doi: 10.1016/j.orcp.2020.07.005. Epub 2020 Jul 23.
3
Organ-specific manifestations of COVID-19 infection.COVID-19 感染的器官特异性表现。
Clin Exp Med. 2020 Nov;20(4):493-506. doi: 10.1007/s10238-020-00648-x. Epub 2020 Jul 27.
4
The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity.宿主遗传学在 SARS-CoV-2 免疫反应和 COVID-19 易感性及严重程度中的作用。
Immunol Rev. 2020 Jul;296(1):205-219. doi: 10.1111/imr.12897. Epub 2020 Jul 13.
5
The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries.24410 名新型冠状病毒（SARS-CoV-2；COVID-19）感染者的症状流行率：来自 9 个国家的 148 项研究的系统评价和荟萃分析。
PLoS One. 2020 Jun 23;15(6):e0234765. doi: 10.1371/journal.pone.0234765. eCollection 2020.
6
Telemedicine, COVID-19 and liver diseases: Revamping remote care initiatives in hepatology.远程医疗、COVID-19与肝脏疾病：重塑肝病学中的远程护理举措
Ann Hepatol. 2020 Jul-Aug;19(4):339-340. doi: 10.1016/j.aohep.2020.05.002. Epub 2020 May 23.
7
The liver in times of COVID-19: What hepatologists should know.COVID-19 时期的肝脏：肝病学家应该了解的知识。
Ann Hepatol. 2020 Jul-Aug;19(4):353-358. doi: 10.1016/j.aohep.2020.05.001. Epub 2020 May 18.
8
Potential implications of COVID-19 in non-alcoholic fatty liver disease.2019冠状病毒病对非酒精性脂肪性肝病的潜在影响。
Liver Int. 2020 Oct;40(10):2568. doi: 10.1111/liv.14484. Epub 2020 May 25.
9
Liver injury in COVID-19: management and challenges.新型冠状病毒肺炎中的肝损伤：管理与挑战
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430. doi: 10.1016/S2468-1253(20)30057-1. Epub 2020 Mar 4.
10
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.2017 年全球疾病负担研究：1990-2017 年 195 个国家和地区按病因划分的肝硬化全球、区域和国家负担：系统分析。
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266. doi: 10.1016/S2468-1253(19)30349-8. Epub 2020 Jan 22.
Zotero 插件